Tomomi Fujii, Yoshihiro Tatsumi and Noboru Konishi
Nara Medical University School of Medicine, Japan
Posters-Accepted Abstracts: J Cancer Sci Ther
Prostate cancer has become a common cancer in men. Although, several treatments such as radical prostatectomy and radiation therapy including brachytherapy have contributed to an improved prognosis for this malignancy, few therapeutic strategies are available for metastatic or hormone-refractory cancers. We have investigated syndecan-1 and/or several microRNA (miRNAs) affect on prostate carcinogenesis, so we investigated whether the micro RNA(miR)-331-3p controlled by syndecan-1 had positive effect on epithelial-to-mesenchymal transition (EMT) in the prostate cancer. The over-expression of miR-331-3p up-regulates mesenchymal markers such as vimentin, N-cadherin and snail, in contrast to down-regulation of epithelial markers such as E-cadherin and desmoplakin in prostate cancer cell line, PC3. We identified Neuropilin 2 and nucleus accumbens-associated protein 1 as putative target molecules, which were closely associated with expression of miR-331-3p and TGF-�²/Smad 4 signals. By in-situ hybridization and immunohistochemistry using radical prostatectomy samples, miR-331-3p was detected in cancer cells with high Gleason patterns, in which EMT was demonstrated by decreased E-cadherin and increased vimentin. Interestingly, syndecan-1 gene silencing decreased Dicer involving miRNA maturation. These findings show that overexpression of miR-331-3p lead to EMT through TGF-�² and Smad signaling associated with syndecan-1 expression. Syndecan-1 plays an important role in the processing of miRNA to maturation by regulating Dicer expression. In addition, syndecan-1 and miR-331-3p may be useful clinical diagnostic and/or prognostic markers.
Email:
fujiit@naramed-u.ac.jpCancer Science & Therapy received 5332 citations as per Google Scholar report